shutterstock-128145248-web

Adam Gregor / Shutterstock.com

31 July 2014Americas

Pfizer acquires Baxter vaccines for $635m

Pfizer has entered into a definitive agreement to acquire two vaccines marketed by US biotechnology company Baxter International for $635 million.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Baxter sues B.Braun in revived kidney treatment patent dispute

16 November 2020 American healthcare multinational Baxter has accused B.Braun of patent infringement and fraudulent misrepresentation in an on-going dispute over products used to treat acute kidney injury.

EC signs contract with Pfizer to access watershed vaccine

12 November 2020 The European Commission has approved a fourth contract with pharmaceutical companies Pfizer and BioNTech, following their revelation that they had developed a vaccine that could potentially prevent more than 90% of people from becoming infected by COVID-19.

More on this story

Baxter sues B.Braun in revived kidney treatment patent dispute

16 November 2020 American healthcare multinational Baxter has accused B.Braun of patent infringement and fraudulent misrepresentation in an on-going dispute over products used to treat acute kidney injury.

EC signs contract with Pfizer to access watershed vaccine

12 November 2020 The European Commission has approved a fourth contract with pharmaceutical companies Pfizer and BioNTech, following their revelation that they had developed a vaccine that could potentially prevent more than 90% of people from becoming infected by COVID-19.

More on this story

Baxter sues B.Braun in revived kidney treatment patent dispute

16 November 2020 American healthcare multinational Baxter has accused B.Braun of patent infringement and fraudulent misrepresentation in an on-going dispute over products used to treat acute kidney injury.

EC signs contract with Pfizer to access watershed vaccine

12 November 2020 The European Commission has approved a fourth contract with pharmaceutical companies Pfizer and BioNTech, following their revelation that they had developed a vaccine that could potentially prevent more than 90% of people from becoming infected by COVID-19.

More features

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Former PTAB judge joins Sterne Kessler

GSK escalates mRNA COVID-19 vaccine dispute

Smart ringleader: Could Ōura’s market dominance be under threat?

The flaw that landed Sanofi a win in the rare disease space

Roche resolves cancer test dispute with Stanford affiliated startup